Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04743765

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

Recruiting

Interested in participating?

Request Info

Key information

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The John Hunter Hospital, New Lambton Heights, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age ≥45 years;
  • diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;
  • troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and
  • informed consent.

Exclusion criteria

  • taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;
  • patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
  • patients with peri-prosthetic fracture, open fracture or bilateral fractures;
  • patients requiring an emergency surgery for another reason (e.g., subdural hematoma);
  • patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;
  • patients refusing consent; or
  • patients previously enrolled in HIP ATTACK-2.

Treatment and study plan

Accelerated medical clearance and surgery

Other

Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.

Primary outcomes

  1. All cause mortality

    Time frame: Within 90 days post randomization

    Death due to all causes

Secondary outcomes

  1. Ability to independently walk 3 meters

    Time frame: Within 90 days post randomization

    Ability to independently walk 3 meters (10 feet) or across a room without human assistance. Patients who require a cane or walker, but not human assistance, will be classified as able to walk independently. Patients who require assistance to get out of a chair, but can walk independently once they get up, will be classified as able to walk independently.

  2. Composite of major complications

    Time frame: Within 90 days post randomization

    Composite includes vascular and nonvascular mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke.

  3. Vascular mortality

    Time frame: Within 90 days post randomization

    Any death with a vascular cause and includes those deaths following a myocardial infarction, sudden cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), heart failure, pulmonary embolus, cardiovascular hemorrhage, or deaths due to an unknown cause

  4. Nonvascular mortality

    Time frame: Within 90 days post randomization

    Any death due to a clearly documented non-vascular cause.

  5. Myocardial Infarction

    Time frame: Within 90 days post randomization

    Diagnosis of MI according to 4th universal definition of myocardial infarction

  6. Acute Congestive Heart Failure

    Time frame: Within 90 days post randomization

    at least one clinical sign(s) or symptom(s) (e.g elevated jugular venous pressure, respiratory rales/crackles, crepitations, hypoxia, tachypnea or presence of S3) with at least one of the following:

    • radiographic findings (i.e., vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema) or point of care ultrasound findings (i.e., bilateral B-lines, bilateral pleural effusion, elevated jugular venous pressure, dilated inferior vena cava with respiratory variation less than 50%) OR
    • heart failure treatment implemented with diuretics with documented clinical improvement.
  7. Stroke

    Time frame: Within 90 days post randomization

    Either - 1. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting more than 24 hours or leading to death; or 2. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting less 24 hours with a positive neuroimaging consistent with a stroke

  8. Time from randomization to hospital discharge

    Time frame: Within 90 days post randomization

    Length of hospital stay from randomization to hospital discharge

  9. Delirium

    Time frame: Within 7 days and 90 days post randomization

    • Patient meets the criteria for delirium on any in-person 3D-CAM or CAM administered; OR
    • Positive history of delirium in the 7 days after randomization based on the review of hospital health records.
  10. Moderate to severe pain

    Time frame: Within 7 days and 90 days post randomization

    Moderate to severe pain is defined as any pain score ≥3 on 10 points scale.

Other outcomes

  1. New clinically important atrial fibrillation or flutter

    Time frame: Within 90 days post randomization

    Documentation of atrial fibrillation or atrial flutter of any duration on an ECG, telemetry tracing, or rhythm strip and results in angina, congestive heart failure, symptomatic hypotension, or is followed by initiation or a dose increase of a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.

  2. Cardiac revascularization procedure

    Time frame: Within 90 days post randomization

    Revascularization procedures including coronary artery bypass graft or percutaneous coronary intervention surgery.

  3. Venous thromboembolism

    Time frame: Within 90 days post randomization

    Venous pulmonary embolism or deep venous thrombosis

  4. Pulmonary embolism

    Time frame: Within 90 days post randomization

    The diagnosis of PE requires any one of the following:

    • A high probability ventilation/perfusion lung scan,
    • An intraluminal filling defect of a segmental or larger artery on a helical CT scan,
    • An intraluminal filling defect on pulmonary angiography, or
    • A positive diagnostic test for DVT (e.g., positive compression ultrasound) and one of the following:

    A. Non-diagnostic (i.e., low or intermediate probability) ventilation/perfusion lung scan B. Non-diagnostic (i.e., subsegmental defects or technically inadequate study) helical CT scan.

  5. Proximal deep venous thrombosis

    Time frame: Within 90 days post randomization

    The diagnosis of proximal DVT requires:

    • Thrombosis involving the popliteal vein or more proximal veins for leg DVT and axillary or more proximal veins for arm DVT, AND
    • Evidence of vein thrombosis by any one of the following:
    • A persistent intraluminal filling defect on contrast venography, 2. Noncompressibility of one or more venous segments on B mode compression ultrasonography, or 3. A clearly defined intraluminal filling defect on contrast enhanced computed tomography.
  6. Infection

    Time frame: Within 90 days post randomization

    Pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms.

  7. Sepsis

    Time frame: Within 90 days post randomization

    Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria,20 sepsis will require a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points or patients requiring vasopressors/inotropes due to infection. The qSOFA includes the following items and scoring system:

    • Altered mental status (1 point),
    • Systolic blood pressure (SBP)of 100 mm Hg or less (1 point), and
    • Respiratory rate (RR) of 22 breaths/min or more (1 point).
  8. Pneumonia

    Time frame: Within 90 days post randomization

    Acute infection of the pulmonary parenchyma that is associated with at least one sign or symptom of lower respiratory acute infection (e.g., cough, pleuritic chest pain) or acute systemic illness (e.g., fever, chills, confusion, hypoxemia); accompanied by the presence of an acute infiltrate/consolidation on a chest radiograph or auscultatory findings consistent with pneumonia (such as crackles and/or localized rales) for which there is no other explanation.

  9. Bleeding

    Time frame: Within 90 days post randomization

    Life threatening, major or critical organ bleeding

  10. Hip reoperation

    Time frame: Within 90 days post randomization

    Any second surgical procedure undertaken on the fractured hip being followed in the study, for any reason (e.g. infection, implant failure, periprosthetic fracture, wound dehiscence, etc.), after it has been initially repaired and the patient has left the operating room.

  11. Prosthetic hip dislocation

    Time frame: Within 90 days post randomization

    Any acute dislocation of a prosthetic femoral head from within its intended concentric location within the acetabulum. The acetabulum may or may not be resurfaced/replaced.

  12. Implant failure

    Time frame: Within 90 days post randomization

    Any mechanical issue related to the integrity of any component of the hip implant which requires a surgical procedure to correct. This includes: loss of implant fixation to bone (either with or without associated periprosthetic fracture); or broken, disassociated, or dislocated implant components.

  13. Peri-prosthetic fracture

    Time frame: Within 90 days post randomization

    Fracture through any part of either the femur and/or acetabulum to which a hip implant used for hip repair/reconstruction was fixed.

  14. Acute kidney injury

    Time frame: Within 90 days post randomization

    An increase in the serum creatinine concentration from the pre-randomization value of ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours after randomization, or an increase of ≥50% within 7 days after randomization.

  15. Acute renal failure resulting in dialysis

    Time frame: Within 90 days post randomization

    New requirement for dialysis (i.e., use of hemodialysis machine or peritoneal dialysis apparatus in patients without a requirement for dialysis prior to randomization).

  16. Hospital re-admission

    Time frame: Within 90 days post randomization

    Hospital re-admission following discharge from index hospitalization

  17. Length of critical care stay

    Time frame: Within 90 days post randomization

    Length of critical care stay

  18. Length of rehabilitation stay

    Time frame: Within 90 days post randomization

    Length of rehabilitation stay

  19. Days alive at home

    Time frame: Within 90 days post randomization

    Days alive at home are the number of days patients spend at their usual residence without, during that day, being admitted to a hospital or visiting an emergency department or urgent-care centre. Patients lose days alive at home if 1. patients go to an emergency department or urgent-care centre; 2. they become inpatients at a hospital or rehabilitation or convalescence-care facility; or 3. they die.

Study contacts

Contact information is provided by the study sponsor or research team.

Valerie Harvey

CONTACT

[email protected]

905-297-3479 ext. 40793

Sponsors and collaborators

Lead sponsor

Population Health Research Institute

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Registry information

Official study title

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 (HIP ATTACK-2) Trial

Acronym: HIP ATTACK-2

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
Feb 8, 2021
Registry last updated
Oct 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.